Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
Clinical trial NCT05150587 · COMPLETED
Trial details
- NCT number
- NCT05150587
- Sponsor
- Alfasigma S.p.A.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-10-05
- Primary completion
- 2022-10-20
- Enrollment
- 216
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.